Divi's Laboratories Q1 FY2027 Net Profit Surges 66% to ₹902 Crore, EBITDA Up 72% on Volume and Mix Shift

The Quick Take

• Divi's Laboratories reported Q1 FY2027 net profit of ₹902 crore, a 66% YoY increase, significantly beating analyst estimates.
• Revenue from operations rose 28% YoY to ₹3,080 crore, driven by API volume recovery and higher-value nutraceutical segment.
• EBITDA jumped 72.2% to ₹1,255 crore as operating leverage and mix shift toward higher-margin custom synthesis drove margin expansion.
• Total expenses rose only 9% YoY against 28% revenue growth — a strong indication of operating leverage across the business.

Divi's Laboratories delivered an exceptional Q1 FY2027 performance that significantly exceeded consensus expectations: net profit rose 66% to ₹902 crore while revenue grew 28% to ₹3,080 crore. Most notably, EBITDA surged 72.2% to ₹1,255 crore — the magnitude of operating leverage reflecting both a recovery in generic API volumes and an accelerating mix shift toward the custom synthesis and specialty nutraceuticals segments, which command materially higher margins than commodity APIs.

Divi's is a structural beneficiary of two intersecting trends in global pharma supply chains. First, Western pharmaceutical companies — accelerated by the COVID-era supply chain fragility experience — are actively diversifying API procurement away from Chinese suppliers toward Indian manufacturers with GMP-certified facilities. Divi's Vizag facility is particularly well-positioned for this shift. Second, demand for high-value custom synthesis (contract development and manufacturing) is growing faster than generic APIs as innovator pharma companies outsource more complex chemistry to trusted partners.

The Q1 result confirms that Divi's recovery — which began with improving API pricing in late 2025 after two years of post-COVID inventory correction — has durability. With total expenses growing only 9% against 28% revenue growth, the company is demonstrating rare operating leverage for a pharmaceutical manufacturer. Watch for management commentary on Q2 guidance and any updates to the Kakinada greenfield expansion timeline; capacity additions at Kakinada would extend Divi's growth runway into FY2028 and beyond.

Synthesized from 2 sources.